Search Results 131-140 of 1191 for 国外ai写作网站,ai 软件下载网站,网文写作ai,ai绘画 生成网站,ai语音克隆网站,等欢迎访问豌豆Ai站群搜索引擎系统官方网站:www.wd.chat

  1. Clinical Trials

    The purpose of this study is to follow Mayo Clinic patients with severe brachial plexus injuries who underwent upper limb amputation. Participation eligibility.

  2. SC16LD6.5 in Recurrent Small Cell Lung Cancer - Mayo Clinic

    5 will be assessed by measuring the extent of tumor shrinkage. SC16LD6.5 is an antibody-drug conjugate (ADC). The antibody (SC16) targets a protein that appears ...

  3. A Study to Evaluate the Implications of the Human Microbiota for Health and Disease - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  4. Xiao Ma - Training and Education - Center for Clinical and Translational Science (CCaTS)

    Profile of Xiao Ma, a student in the Ph.D. Program at Mayo Clinic.

  5. Phase I/​II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/​Without Prior 177Lu-PSMA RLT - Mayo Clinic

    About this study. This is an open label, phase I/II, multi-center study in adult participants with metastatic hormone sensitive prostate cancer (mHSPC) and ...

  6. A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma - Mayo Clinic

    The purpose of this study is to define the recommended dose, safety, tolerability, immunogenicity, and preliminary effectiveness of EO2463 during monotherapy ...

  7. Genetic Markers of Cardiovascular Disease in Epilepsy - Mayo Clinic

    Some of these conditions which affect heart and brain have an identifiable genetic cause. This study aims to identify known genetic causes of heart rhythm and ...

  8. Mayo Clinic-Trained Transplant Surgeon Instills Educational Excellence in Next Generation - News Archive

    Transplant surgeon, Timucin Taner, M.D., Ph.D., and fellow, Omar Haque, share their experiences in Mayo Clinic School of Graduate Medical Education.

  9. Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other Myelodysplastic /Myeloproliferative Neoplasias, and Acute Myeloid Leukemia - Mayo Clinic

    In the absence of unmanageable toxicities, subjects may continue to receive tipifarnib treatment until disease progression. If a complete response is observed, ...

  10. Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma - Mayo Clinic

    Tipifarnib will be administered until disease progression then followed approximately every 12 weeks for survival until either death or 12 months after accrual ...